US 2016/0354489 A1 · GENE THERAPY COMPOSITIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

Abstract

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (NAFLD). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (AAV) containing the gene encoding Sirtuin 1 (Sirt1) in the prevention and/or treatment of NAFLD. The present invention also discloses the pharmaceutical compositions comprising the viral vector and the method of prevention and/or treatment of NAFLD and related diseases by the administration of said pharmaceutical compositions.

Claims14

Dependent claims

A viral construct comprising a nucleotide sequence encoding Sirtuin 1 (Sirt1), or a functionally equivalent variant thereof, said viral construct being operably linked to a liver-specific promoter.

Dependencies are inferred from the claim text.

Facts

Application

15/024,821Filed 25 Sep 2014

Priority

EP 13382369.026 Sep 2013

Published

8 Dec 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 48/0058
Characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered: nucleic acids adapted for tissue…
A61K 38/50
Hydrolases: acting on carbon-nitrogen bonds, other than peptide bonds , e.g. asparaginase
A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…
C12N 7/00
Viruses

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

Life of this patent

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

Life of this patent

Abstract

Claims14